Arvinas Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Arvinas Inc's ROI in the second quarter of 2026?
Arvinas Inc achieved a return on average invested assets (ROI) of 1.55 % in its second quarter of 2026, this is above ARVN's average return on investment of -43.47%.
Arvinas Inc invested over the 12 months ending in its second quarter of 2026 $600 million

ROI has improved compared to -33.42% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 172 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3536, from total ROI ranking in the first quarter of 2026 at 3647.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-29.07 %	-23.72 %	-20.59 %	-16.98 %	-8.41 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	593	532	575	699	842
Return On Investment (TTM)	1.55 %	-33.42 %	-11.13 %	-7.33 %	-8.59 %
ARVN's Overall Ranking	# 3536	# 3647	# 3078	# 3115	# 2987
Seq. Investment Change TTM	-9.42 %	-8.8 %	-8.97 %	-5.67 %	-2.6 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	9	-221	-81	-59	-73

ARVN Company Profile >> Back to ARVN Roi Comparisons >> See Annual ARVN Return On Investment

Return On Investment ARVN's Ranking
Within:	No.
Industry	# 58
Sector	# 173
Overall	# 3536

Return On Investment Statistics
High	Average	Low
1.53 %	-43.47 %	-457.81 %
(Jun 30 2026)		(Mar 31 2019)

News about Arvinas Inc Return on Investment ROI

Arvinas Announces Chief Financial Officer Transition and Records Impressive 215.31% Stock Improvement in the Last 3 Months

February 20, 2024

Arvinas Inc., a leading biotechnology company specializing in targeted protein degradation, has recently announced the transition of its Chief Financial Officer (CFO), Sean Cassidy, effective February 29, 2024. This significant change in leadership comes at a time when the company has witnessed remarkable growth and success, as evidenced by the impressive 215.31% improvement in its stock value over the past three months.
Sean Cassidy, who has been an instrumental figure in Arvinas financial operations, has decided to part ways with the company. His departure marks the end of an era, as he has contributed immensely to Arvinas growth and has played a key role in the company s financial strategy. The exact reasons for his departure have not been disclosed, but it is evident that Cassidy s tenure has been fruitful for Arvinas.

Arvinas Bolsters Legal Team, Appoints Jared Freedberg as General Counsel and Grants Inducement Package in Compliance with Nasdaq Listing Rule 5635(c)(4)

January 16, 2024

Arvinas Inc., a leading biopharmaceutical company specializing in targeted protein degradation, has taken significant steps to strengthen its legal capabilities with the appointment of Jared Freedberg as General Counsel. In recognition of his expertise and to align with regulatory requirements, the company has also awarded Mr. Freedberg an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4).
With a commitment to driving innovation through its unique PROTAC® platform, Arvinas has experienced tremendous growth in recent years. Understanding the importance of having strong legal guidance to navigate the complexities of the biopharmaceutical industry, the company has strategically appointed Mr. Freedberg to lead its legal team.
Mr. Freedberg brings a wealth of experience and expertise to his role as General Counsel. Previously serving as the Senior Vice President, General Counsel, and Corporate Secretary at a prominent biotechnology firm, he has demonstrated a deep understanding of the legal intricacies surrounding drug development and commercialization. His strategic insights and legal acumen will prove invaluable to Arvinas as the company continues to progress its robust portfolio of protein degrader therapeutics.

Financial Statements
Arvinas Inc's II. Quarter Investments	$ 593 Millions	ARVN's Balance sheet
Arvinas Inc's II. Quarter Income	$ 169 Millions	Quarterly ARVN's Income Statement
ARVN's Income by Division		See ARVN's Income by Division

ARVN Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	575	862	1,048	974	1,320
Y / Y Investment Growth	-33.22 %	-17.75 %	7.58 %	-26.23 %	104.11 %
Net Income in Millions	-81	-199	-367	-283	-191
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-14.04 %	-23.08 %	-35.06 %	-29.01 %	-14.47 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ARVN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ARVN's Competitors
Subscribers only: Roi for Arvinas Inc's Suppliers
Subscribers only: Return On Investment for ARVN's Customers

Other Ratios
ARVN's Roa	ARVN's Inventory Turnover Ratio	ARVN's Growth Rates	ARVN's Dividend Statistics
	ARVN's Profitability Ratios	ARVN's Asset Turnover Ratio	ARVN's Dividend Growth
ARVN's Roe	ARVN's Valuation Ratios	ARVN's Financial Strength Ratios	ARVN's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Zimmer Biomet Holdings Inc	3.97 %
U S Physical Therapy Inc	3.91 %
Privia Health Group Inc	3.90 %
Integer Holdings Corporation	3.88 %
Ardent Health Inc	3.74 %
Collegium Pharmaceutical Inc	3.72 %
Merck and Co Inc	3.24 %
Community Health Systems Inc	3.12 %
National Vision Holdings Inc	2.99 %
Teva Pharmaceutical Industries Limited	2.66 %
Lifestance Health Group Inc	2.61 %
Conmed Corporation	2.57 %
Pfizer Inc	2.53 %
Mimedx Group Inc	2.38 %
Bio rad Laboratories Inc	2.34 %
Lifemd Inc	2.32 %
Alkermes Plc	2.31 %
Becton Dickinson And Company	2.22 %
Revvity Inc	2.18 %
Envista Holdings Corporation	2.06 %
Immucell Corporation	1.95 %
Atricure Inc	1.84 %
Black Hawk Acquisition Corporation	1.79 %
Omada Health Inc	1.70 %
Arvinas Inc	1.53 %
Repligen Corp	1.41 %
Cormedix Inc	1.31 %
Pacira Biosciences inc	1.29 %
Waters Corporation	1.20 %
Surgery Partners Inc	1.02 %

Date modified: 2026-09-26T07:34:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.